Literature DB >> 15935490

Structure-activity studies on different modifications of nociceptin/orphanin FQ: identification of highly potent agonists and antagonists of its receptor.

Min Chang1, Ya-Li Peng, Shou-Liang Dong, Ren-Wen Han, Wei Li, Ding-Jian Yang, Qiang Chen, Rui Wang.   

Abstract

Nociceptin/orphanin FQ (N/OFQ) and its receptor system modulate a variety of biological functions and further understandings of physiological and pathological roles of this system require new potent agonists and antagonists of its receptor. Two series of N/OFQ related analogues were synthesized to investigate the relationship of different modifications. We combined modifications including: (a) Phe(4)-->(pF)Phe(4); (b) Ala(7), Ala(11)-->Aib(7), Aib(11); (c) Leu(14), Ala(15)-->Arg(14), Lys(15). Compared with the first series, N-terminus of the second series was changed from Phe(1) to Nphe(1). All the analogues were amidated at C-terminus. These compounds were tested in binding studies on rat brain membranes and mouse vas deferens assay. Results indicated that the compounds of the first series showed higher affinity and potency than N/OFQ (pK(i)=9.33; pEC(50)=7.50). In particular, [(pF)Phe(4), Aib(7), Aib(11), Arg(14), Lys(15)] N/OFQ-NH(2) was found to be a highly potent agonist with pK(i)=10.78 in binding studies and pEC(50)=9.37 in mouse vas deferens assay. The second series all competitively antagonized the effects of N/OFQ in mouse vas deferens assay. [Nphe(1), (pF)Phe(4), Aib(7), Aib(11), Arg(14), Lys(15)] N/OFQ-NH(2) was the best antagonist with pA(2)=8.39 and showed high binding affinity with pK(i)=9.99. Thus modifications which increase the potency of agonist have synergistic effect on biological activity and a replacement of N-terminus leads to shift of analogues from agonist to antagonist.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15935490     DOI: 10.1016/j.regpep.2005.04.005

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  4 in total

Review 1.  UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.

Authors:  Girolamo Calo'; Anna Rizzi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Domenico Regoli; Maurizio Massi; Severo Salvadori; David G Lambert; Remo Guerrini
Journal:  CNS Neurosci Ther       Date:  2010-05-18       Impact factor: 5.243

2.  In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor.

Authors:  Anna Rizzi; Barbara Spagnolo; Richard D Wainford; Carmela Fischetti; Remo Guerrini; Giuliano Marzola; Anna Baldisserotto; Severo Salvadori; Domenico Regoli; Daniel R Kapusta; Girolamo Calo
Journal:  Peptides       Date:  2007-05-06       Impact factor: 3.750

3.  Neuropeptide S facilitates mice olfactory function through activation of cognate receptor-expressing neurons in the olfactory cortex.

Authors:  Yu-Feng Shao; Peng Zhao; Chao-Yu Dong; Jing Li; Xiang-Pan Kong; Hai-Liang Wang; Li-Rong Dai; Yi-Ping Hou
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

4.  In vitro pharmacological characterisation of a novel cyclic nociceptin/orphanin FQ analogue c[Cys(7,10)]N/OFQ(1-13)NH (2).

Authors:  M Kitayama; J McDonald; T A Barnes; G Calo'; R Guerrini; D J Rowbotham; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-06-28       Impact factor: 3.195

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.